Ata Ch Treatment Formulations Against

---
name: ata-ch-treatment-formulations-against
description: Recommend against using levotriiodothyronine (L-T3), thyroid extracts, or other thyroid hormone formulations for central hypothyroidism. Triggered when evaluating thyroid hormone replacement in central hypothyroidism (e.g., 'considering thyroid hormone replacement for central hypothyroidism' or 'central hypothyroidism requiring thyroid hormone replacement').
---

# Recommend against treating central hypothyroidism with specific thyroid hormone formulations

## STEP 1 — Gather Information
Collect serum free T4 (fT4) and TSH to confirm central hypothyroidism (low fT4 with low/normal/mildly elevated TSH in context of pituitary disease), assess symptoms of hypothyroidism, and determine need for thyroid hormone replacement.

## STEP 2 — Rule In / Rule Out
Is central hypothyroidism confirmed and thyroid hormone replacement indicated? If yes, proceed; if no, do not initiate thyroid hormone therapy.

## STEP 3 — Classify or Stratify
Determine whether the proposed thyroid hormone formulation is L-T3, thyroid extracts, or other non-L-T4 formulations versus standard L-T4 therapy.

## STEP 4 — Decide
Recommend against using L-T3, thyroid extracts, or other formulations; prescribe L-T4 to achieve fT4 levels in the mid-to-upper half of the reference range, adjusting dose based on clinical context, age, and fT4 levels.

## Clinical Guardrails / Mimics / Pitfalls
Do not rely on TSH levels to monitor or adjust therapy in central hypothyroidism, as TSH may be low, normal, or mildly elevated and does not correlate with fT4. Avoid L-T3 due to risk of supra-physiologic T3 levels and potential overtreatment; thyroid extracts have variable hormone ratios and lack standardized dosing.

## Concrete Clinical Example
A 45-year-old woman with pituitary macroadenoma and confirmed central hypothyroidism (low fT4, normal TSH) is being considered for thyroid hormone replacement. Instead of prescribing L-T3 or desiccated thyroid, the clinician initiates L-T4 at 1.6 µg/kg/day and adjusts dose to maintain fT4 in the target range.

## Source
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2016-2118